New malaria vaccine dosing strategy tested in Early-Stage trial
NCT ID NCT06320535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether giving the R21/Matrix-M malaria vaccine in a new, escalating-dose schedule is safe and creates a strong immune response. It involves 36 healthy adults in the UK who have never had malaria. The goal is to find a better way to protect people from this serious disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA FALCIPARUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Clinical Vaccinology and Tropical Meducine, Churchill Hospital, University of Oxford
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol, BS2 8HW, United Kingdom